Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Dengue Vaccine Market Growth From $0.61 Billion In 2026 To $1.15 Billion By 2030 At A CAGR Of 17.3%
The dengue vaccine market has seen rapid expansion in recent times. Projections indicate its expansion from $0.51 billion in 2025 to $0.61 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 20.2. Historically, this expansion has been driven by factors such as an increase in dengue infection rates, scarcity of initial vaccines, a heightened public health burden, greater understanding of mosquito-borne illnesses, and prompt government intervention programs.
The dengue vaccine market size is projected for substantial expansion in the coming years, reaching $1.16 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 17.3. This anticipated growth during the forecast period is fueled by factors such as the broadening of immunization initiatives, increased funding for vaccine research, elevated healthcare expenditure in regions where dengue is prevalent, a heightened emphasis on the effectiveness of multi-strain vaccines, and expedited regulatory authorizations. Key trends anticipated for this period involve an escalating global commitment to dengue prevention, the proliferation of government-sponsored vaccination campaigns, wider acceptance of tetravalent dengue vaccines, an increase in public health funding within endemic areas, and a growing need for immunization options for children.
Download A Free Sample Report For Comprehensive Market Insights:
Dengue Vaccine Market Industry Drivers: What Is Driving Revenue Growth?
The increasing incidence of dengue fever is projected to fuel the expansion of the dengue vaccine markets in the future. This viral infection, transmitted by Aedes aegypti mosquitoes, manifests with symptoms such as high fever, headaches, joint pain, and rashes. Several factors contribute to the surge in dengue fever, including climate change, increasing urbanization, insufficient mosquito control measures, and the evolution of the virus. The dengue vaccine operates by stimulating the immune system, enabling it to recognize and fight the dengue virus. Its mechanism helps mitigate the severity of the infection and lowers the likelihood of serious complications, thereby contributing to a reduction in cases and hospital admissions. For example, as reported by the World Health Organization, a Switzerland-based intergovernmental organization, in May 2024, the American region recorded over 7 million dengue cases by April 2024, an increase from 4.6 million cases documented in 2023. Consequently, the growing prevalence of dengue fever is propelling the expansion of the dengue vaccine market.
Dengue Vaccine Market Segmentation: How Is The Market Structured Across Key Categories?
The dengue vaccine market covered in this report is segmented –
1) By Type: Live Attenuated Vaccine, Chimeric Live Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccine, Nucleic Acid Based Vaccine
2) By Vaccine Phase: Phase I, Phase II, Phase III
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By End-User: Hospitals, Clinics, Government Institutes, Non-Governmental Organizations, Other End-Users
Subsegments:
1) By Live Attenuated Vaccine: Single Strain, Multi-Strain
2) By Chimeric Live Attenuated Vaccine: Tetravalent Chimeric Vaccine, Monovalent Chimeric Vaccine
3) By Inactivated Vaccine: Whole Virus Inactivated Vaccine, Split Virus Vaccine
4) By Subunit Vaccine: Recombinant Protein Vaccine, Peptide-Based Vaccine
5) By Nucleic Acid Based Vaccine: DNA Vaccine, mRNA Vaccine
#Dengue Vaccine Market Growth Trends: What Is Influencing The Future Outlook?
Leading firms within the dengue vaccine market are prioritizing clinical investigations to create advanced vaccine types, notably live attenuated vaccines, aiming to deliver extensive and enduring defense against all four dengue virus serotypes. These live attenuated vaccines employ a weakened viral strain, incapable of inducing illness in healthy people, yet effective in prompting the immune system to build robust, sustained, and comprehensive immunity, equipping the body to identify and combat the actual virus upon future exposure. An example of this effort is seen in June 2025, when Merck & Co. Inc., a pharmaceutical entity based in the US, commenced the MOBILIZE-1 Phase 3 clinical trial to assess V181, its experimental live attenuated quadrivalent dengue vaccine. The study plans to enlist around 12,000 healthy children and adolescents aged 2 to 17 residing in dengue-prevalent nations across the Asia-Pacific region, specifically Indonesia, Malaysia, Philippines, Singapore, Thailand, and Vietnam. This trial is structured as a randomized, double-blind, placebo-controlled investigation intended to gauge the safety, immunogenicity, and effectiveness of a solitary dose of V181 against all four dengue virus serotypes, irrespective of any previous dengue exposure. The vaccine aims to address symptomatic dengue across all levels of severity, encompassing severe manifestations potentially necessitating hospitalization, and endeavors to offer extensive, enduring protection to alleviate the worldwide impact of this swiftly propagating mosquito-transmitted illness.
Dengue Vaccine Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the dengue vaccine market are Merck & Co. Inc., Sanofi Pasteur Limited, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Biological E. Limited, Saint Louis University, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Instituto Butantan, Bharat Biotech Ltd., Panacea Biotec Limited, SABIN Vaccine Institute, Medigen Vaccine Biologics Corporation, Emergex Vaccines Holding Ltd., BioNet-Asia Co. Ltd., Codagenix Inc., KM Biologics Co. Ltd., Chula Vaccine Research Center, Imutex Ltd.
Access The Complete Dengue Vaccine Market Report:
Dengue Vaccine Market Global Footprint: Which Region Holds Market Leadership?
Asia-Pacific was the largest region in the dengue vaccine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengue vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Customized Dengue Vaccine Market Report for Deeper Competitive Insights
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.
